Cantargia publishes preclinical results showing CAN10 reduces lung and skin fibrosis in systemic sclerosis, advances to Phase II trials.

Cantargia announced publication of preclinical results for CAN10 in systemic sclerosis in the 'Annals of the Rheumatic Diseases'. CAN10 reduces lung and skin fibrosis in preclinical models, with its target, IL1RAP, being upregulated and disease-promoting in systemic sclerosis patients. The antibody is in phase I clinical development, and Cantargia is preparing for phase II clinical trials.